top of page
Search
All Posts
New update from the International Severe Asthma Registry (ISAR)!
New real-world insights from the International Severe Asthma Registry (ISAR), spanning data from over 25 countries, have been featured in...
3 days ago1 min read
Biologics for asthma prevent new-onset diabetes, major adverse cardiovascular events (MACE) as well as other oral corticosteroid (OCS)-related adverse events: Ground-breaking results from SOLAR II
The real-world SOLAR II study shows that biologic initiators had 18% lower risk of developing any oral corticosteroid (OCS)-related...
4 days ago3 min read
Switching or stopping biologic therapy was associated with worse clinical outcomes than continuing the initial therapy: Results from CLEAR
A recently published study in Pragmatic and Observational Research, “Real-world biologic use patterns in severe asthma, 2015–2021: the...
Mar 183 min read
Global disease burden of patients with severe asthma, regardless of biologic accessibility and receipt of biologic treatment: Results from EVEREST
The EVEREST study published in the Journal of Asthma and Allergy, “Disease Burden and Access to Biologic Therapy in Patients with Severe...
Dec 16, 20243 min read
Exploring different composite definitions of responders to biologic treatment for severe asthma (FULL BEAM Response)
The International Severe Asthma Registry (ISAR)’s new study, “Exploring definitions and predictors of response to biologics for severe...
Jul 10, 20243 min read
Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults (FULL BEAM Remission)
We are excited to share groundbreaking findings on remission as a therapeutic target in "Exploring definitions and predictors of severe...
Jul 9, 20242 min read
International research collaboration affirms benefits of biologic therapies across broad severe asthma patient populations worldwide, but also highlights unmet treatment needs: Results from LUMINANT
Singapore, [25 June 2024] – A new analysis of data from the International Severe Asthma Registry (ISAR) has revealed a spectrum of...
Jun 25, 20243 min read
Ground-breaking new study from ISAR uncovers the power of asthma tests BEC and FeNO to predict effectiveness of biologic therapies in Severe Asthma
A new real-world research study from ISAR, the International Severe Asthma Registry, reveals the strength of the asthma tests...
May 9, 20242 min read
New ISAR Research Sheds Light on Asthma Exacerbation Rates: Great Variability Found Across Nations
The International Severe Asthma Registry is a global collaborative initiative to gather anonymous, longitudinal, real-life data for...
Apr 25, 20241 min read
New evidence reveals the power of biologics to improve severe asthma outcomes in patients with T2 comorbidities
ISAR ’s new publication "Association between T2-related co-morbidities and effectiveness of biologics in severe asthma” to the highly...
Mar 15, 20241 min read
Latest ISAR research reveals the significant impact of pre-existing health on response to treatment with biologics in Severe Asthma
Important progress has been gained in the journey towards understanding response to biologic therapy in severe asthma through the...
Feb 23, 20242 min read
New inventory of severe asthma registries unlocks potential for global research and best care
ISAR ’s new publication ‘ Adult severe asthma registries: a global and growing inventory ’ to the journal Pragmatic and Observational...
Nov 6, 20231 min read
A greater number of comorbidities is associated with poorer outcomes among adults with severe asthma
The International Severe Asthma Registry (ISAR)’s newest study has determined comorbidities and multimorbidity to be frequent in adults with
Oct 18, 20231 min read
Biologics dramatically reduce steroid requirements and exacerbation rates in severe asthma patients
The International Severe Asthma Registry (ISAR)’s newest study has found that keeping severe asthma patients on high oral corticosteroid...
Jul 25, 20231 min read
bottom of page